Product logins

Find logins to all Clarivate products below.


Acute Myeloid Leukemia | Niche and Rare Pharmacor | G7 | 2015

Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population.

A range of therapies are used to treat AML; however, the market is dominated by the use of agents that induce DNA damage. As drug treatments and clinical trial designs continue to evolve, novel agents with new mechanisms of action are set to enter this market.

Related Market Assessment Reports

Report
Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…
Report
Acute Myeloid Leukemia | China In-Depth | China | 2022
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Report
Acute Myeloid Leukemia | Disease Landscape & Forecast | G7 | 2024
Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has been the mainstay AML treatment for a long time, the recent…
Report
Acute Myeloid Leukemia – Current Treatment – Treatment Sequencing
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Acute Myeloid Leukemia – Current Treatment – Current Treatment: Physician Insights
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, the prognosis has been poor. Chemotherapy backbones have long dominated treatment, but there is an ongoing…